Salt and crystal form of anti-tumor heterocyclic compound
AssigneeCspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
InventorsYunfeng TIAN, Qiaoli CUI, Shasha WU, Feng GUO, Lei FENG, Miao NIU, Feng LIU, Pengfei LI, Dong ZHAO, Bin MI
Life of this patent
Estimating the term…
Abstract
A crystal form of a free base of compound I, a salt of compound I and a crystal form of the salt of compound (I) are provided. The crystal form and the salt form have excellent effects in terms of physical stability, chemical stability, and hygroscopicity.
Claims30
A crystal form A of compound I, wherein the structure of compound I is as follows:
- the crystal form A has characteristic peaks at 2θ angles of 4.0±0.2°, 18.4±0.2°, 20.3±0.2°, and 21.8±0.2° in an XRPD pattern using Cu-Kα radiation;
- preferably, the crystal form A has characteristic peaks at 2θ angles of 4.0±0.2°, 14.7±0.2°, 15.8±0.2°, 18.4±0.2°, 20.3±0.2°, and 21.8±0.2° in the XRPD pattern using Cu-Kα radiation;
- more preferably, the crystal form A has characteristic peaks at 2θ angles of 4.0±0.2°, 7.1±0.2°, 13.6±0.2°, 14.7±0.2°, 15.8±0.2°, 18.4±0.2°, 20.3±0.2°, 21.8±0.2°, and 27.7±0.2° in the XRPD pattern using Cu-Kα radiation;
- further preferably, the crystal form A has an XRPD pattern substantially as shown in FIG. 1.
(canceled)
A salt of compound I, wherein the structure of compound I is as follows:
- the salt is a hydrochloride, hydrobromide, phosphate, sulfate, methanesulfonate, p-toluenesulfonate, camphorsulfonate (e.g., L-camphorsulfonate), oxalate, maleate, tartrate (e.g., L-tartrate), fumarate, citrate, malate (e.g., L-malate), glycolate or benzoate of compound I.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.